The Bull Rankings scorecard — our quality-growth score is 70.2 / 100, built from three pillars scored 0–100: Quality 83, Growth 66, Value 63 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 8% next year, then recovering toward 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
DocuSign is a high-quality compounder priced like a turnaround story. The market has knocked 31% off its 52-week high, yet the business grew revenue 8.4% in the year ended April 2026 while generating $1.1 billion in trailing free cash flow. Our model gives it a 70.2/100 quality-growth score, with the Quality pillar at 83 and Growth at 66. The Quality score is deserved: return on equity sits at 17.3%, debt to equity is a conservative 0.1, and the company is buying back stock. That’s the anchor. The Growth pillar is weaker at 66, but still solid. The market hasn’t priced in the durability of the franchise; it’s pricing in a slow-growth future. The stock’s 38.5 trailing P/E looks rich, but the 0.73 PEG says the price is modest for the earnings growth analysts expect.
What the business actually is
DocuSign sells an AI-powered intelligent agreement management platform that spans the entire lifecycle of contracts. The core e-signature product lets users send and sign agreements across devices. Contract Lifecycle Management automates workflows from drafting to renewal. Document Generation churns out custom agreements on demand. Identify verifies signer identities with government IDs, and Standards-Based Signatures ensure compliance across borders. These aren’t bolt-on features; they’re layers built on the same platform. That’s the revenue engine: a sticky subscription base that DocuSign can sell more products into over time.
Why it can (or can't) keep compounding
The moat is the network of agreements, not the signature itself. Competitors can copy e-signature features, but replicating the breadth of integrations, compliance certifications, and AI-driven insights across the full lifecycle is a multi-year project. The durability shows in the numbers: a 9.6% profit margin, 8.4% revenue growth and a 17.3% return on equity. That’s the Quality pillar in action. The model’s “Buying back stock” signal points to management’s confidence in that cash generation. The risk isn’t execution; it’s whether the AI layer can keep expanding the TAM fast enough to offset any slowdown in core e-signature growth. The Growth pillar at 66 reflects that uncertainty. But the platform’s design means growth doesn’t hinge on signing new logos; it hinges on deepening usage within existing customers. That’s harder for competitors to disrupt.
The valuation question
The price assumes pessimism, not optimism. Our reverse DCF implies the stock embeds roughly -8% annual free-cash-flow growth (in year one, recovering toward 3% a year by year ten). That’s a bet that DocuSign’s cash flow will shrink, not grow, despite the business expanding revenue 8.4% in the latest year. The market is pricing in a slow death spiral, not a turnaround. The forward P/E of 14x, cited by multiple outlets this month, is cheap unless you believe the cash flow is about to collapse. But the company generated $1.1 billion in trailing free cash flow as of April 2026, and the balance sheet is pristine. The PEG ratio of 0.73 points the same way: the multiple is low for the earnings growth analysts expect. Either the market is wrong about the growth outlook, or it’s right and the stock is a value trap. The tension isn’t resolved by the numbers; it’s resolved by whether AI can unlock new layers of productivity inside the agreement lifecycle.
The bear case
The strongest skeptic’s argument is the implied free-cash-flow decline of -8% per year. If that materializes, today’s price is only fair. The bear case isn’t that DocuSign fails; it’s that the market’s pessimism is justified. Revenue growth of 8.4% isn’t enough to offset the multiple compression if AI adoption slows or competitors erode pricing power. The softest pillar in our model—Value at 63—still sits on the cheap side of peers, which is that skepticism showing up in the price. The market isn’t rewarding the quality; it’s pricing in the risk that the growth engine stalls. That’s the bet investors are making when they walk away from a 17.3% ROE and $1.1 billion in free cash flow.
What would change our mind
First, revenue growth slowing well below 8.4% for two consecutive quarters would suggest the market’s pessimism is warranted. Second, if the reverse DCF implied growth moved from -8% to positive territory, the valuation question would flip from “pessimism priced in” to “optimism justified.” Third, profit margins slipping well below 9.6% would suggest the AI layer is costing more than it earns. Until one of those happens, the stock is a high-quality business trading at a discount to its own fundamentals—a rare setup, but not a guarantee. The market’s skepticism is the opportunity, and the risk.